Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
This star-forming galaxy is blowing out powerful winds topping 2 million mph - 2Bronze Age "City of Seven Ravines" unearthed in central Asia after 3,500 years
- 3'Stranger Things' character guide: The nerds, the newcomers and the rest of the Season 5 cast
- 4Two separate Israeli espionage cases uncover Iran-linked activities in Jerusalem, Ashkelon
- 5Make your choice for a definitive Christmas getaway destination!
- Picking the Right Air Purifier for Your Home
- Which Diet Prompts the Incomparable Wellbeing Results?
- Vehicle Lovers' Decision: Purchase A Reasonable Vehicle
- Moon rush: These private spacecraft will attempt lunar landings in 2026
- The Golden Globes gift bag has nearly $1 million worth of swag for some winners and presenters. What's in it?
- Thousands of genomes reveal the wild wolf genes in most dogs’ DNA
- After harsh winter, Ukrainians find joy in releasing bats rescued from war
- Israel issues notice that Ben-Gurion Airport flights likely restricted until at least April 16
- 7 Logically Demonstrated Techniques for Better Rest
